A retrospective chart review of Voretigene Neparvovec in patients with Inherited Retinal Disease (IRD) caused by RPE65 Gene Mutations: Natural History Study

Trial Profile

A retrospective chart review of Voretigene Neparvovec in patients with Inherited Retinal Disease (IRD) caused by RPE65 Gene Mutations: Natural History Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Voretigene neparvovec (Primary)
  • Indications Leber congenital amaurosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jan 2017 New trial record
    • 09 Jan 2017 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top